← Eichor
Study identifier: NCT03568266 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Pharmacogenomics of Asparaginase Induced Hepatotoxicity

Condition: Acute Lymphoblastic Leukemia  ·  Sponsor: University of Southern California

PhaseN/A
Planned participants500
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.

This description comes directly from the study's public registry record.

Talk to the study team

Christine Duran  ·  323-865-0371  ·  Duran_C@med.usc.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Los Angeles General Medical CenterLos Angeles, California, United StatesRecruiting
USC / Norris Comprehensive Cancer CenterLos Angeles, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03568266